Evaluating ODC-IL2 for advanced or metastatic solid tumors

A Phase 1/1b, Multicenter, Open-label, Dose Escalation and Expansion Study Evaluating the Safety, Pharmacodynamics, and Pharmacokinetics of ODC-IL2 Administered Via Intravenous Infusion in Adult Patients With Advanced or Metastatic Solid Tumors

This study is testing a new treatment called ODC-IL2 to see if it is safe and can help adults with advanced or metastatic solid tumors.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Trutino Biosciences Inc. (Industry-sponsored)
• Drugs / interventions: chemotherapy, radiation
• Locations: 1 site (Scottsdale, Arizona)
• Trial ID: NCT06770764 on ClinicalTrials.gov

What this trial studies

This is a first-in-human, Phase I, multicenter, open-label study designed to assess the safety and preliminary antitumor activity of ODC-IL2 in adult patients with advanced or metastatic solid tumors. The study involves a dose escalation phase where up to 30 patients will receive varying doses of ODC-IL2, followed by a dose expansion phase enrolling approximately 20 additional patients at the maximum tolerated dose. ODC-IL2, a conditionally activated IL-2 prodrug, will be administered via intravenous infusion on specific days of a 28-day treatment cycle. The primary goal is to evaluate the safety, pharmacodynamics, and pharmacokinetics of the drug.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with advanced or metastatic solid tumors that are not amenable to standard treatments.

Not a fit: Patients with early-stage tumors or those who have not exhausted standard treatment options may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for patients with advanced solid tumors that have not responded to existing therapies.

How similar studies have performed: While this approach is novel, similar studies evaluating IL-2 prodrugs have shown promise in early phases.

Eligibility criteria

Inclusion Criteria:

Each patient must meet all the following criteria to participate in the study:

1. Histologically or cytologically confirmed advanced or metastatic solid tumors, for which no other standard treatment is available or appropriate, or for which the Trutino Biosciences Protocol #: TRT-ODC-IL2-001 Version: 1.0 Date: 20 September 2024 standard of care is refused by the patient due to tolerability or the Investigator believes the patient will not tolerate standard-of-care therapy
2. Advanced or metastatic tumors measurable per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria;
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
4. Life expectancy of at least 3 months;
5. Age ≥ 18 years;
6. Signed, written Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent
7. Acceptable liver function:

   * Bilirubin ≤ 1.5 times upper limit of normal (ULN) or ≤ 5 × institutional ULN for patients who have serum bilirubin increases due to underlying Gilbert's Syndrome (familial benign unconjugated hyperbilirubinemia).
   * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 x ULN (if liver metastases are present, then ≤ 5 x ULN is allowed)
8. Acceptable renal function:

   • Calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault equation.
9. Acceptable hematologic status:

   * Absolute neutrophil count ≥ 1500 cells/mm3
   * Platelet count ≥ 75,000 (plt/mm3)
   * Hemoglobin ≥ 9 g/dL
10. A negative serum pregnancy test (if a woman of childbearing potential);
11. Women of childbearing potential (WOCBP) and men with WOCBP partners must agree to use adequate contraception (hormonal method of birth control; intrauterine devices or abstinence) prior to study entry, for the duration of study participation and for 4 months after the last dose of study drug. Should a female trial participant or a female partner of a male trial participant become pregnant or suspect she is pregnant during the study, the Investigator must be informed immediately.

Exclusion Criteria:

1. New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on electrocardiogram (ECG)
2. Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of \> 470 msec
3. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
4. Known active brain metastases; patients with previously treated, clinically stable, radiologically stable brain metastases (without evidence of progression in 4 weeks) and without the requirement for treatment with corticosteroids in prior 3 weeks may be considered for enrollment after discussion with the Medical Monitor
5. History of prior organ transplant
6. Conditions requiring systemic treatment with corticosteroids or any other form of immunosuppressive therapy within 7 days prior to start of study drug.
7. History of autoimmune diseases requiring systemic immunosuppressive therapy in the last 2 years
8. Pregnant or nursing women.
9. Treatment with radiation therapy, major surgery, chemotherapy, or investigational therapy within 4 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C). Radiation for palliation of pain is allowed within 1 week prior to study entry, but the lesion should not be selected as a target lesion for RECIST analysis.
10. Unwillingness or inability to comply with procedures required in this protocol
11. Known active infection with human immunodeficiency virus (HIV), human T-cell leukemia virus, type 1 (HTLV-1), hepatitis B virus (HBV), or hepatitis C virus (HCV)

    * Patients with a history of hepatitis B or C are allowed if HBV DNA or HCV RNA are undetectable
    * Active infection with HIV and CD4+ T-cell count \<350/μL. Patients not on established anti-retroviral therapy for at least 4 weeks and having a detectable HIV viral load
12. Serious uncontrolled nonmalignant disease (e.g., renal failure, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor
13. Prior treatment with an IL-2 targeted treatment, unless given as a part of a tumor infiltrating lymphocyte treatment combination;
14. Known sensitivity to IL-2 or any of the excipients in ODC-IL2;
15. Active treatment with heparin or heparin-related therapies, unless the patient can be transitioned to a non-heparin treatment for the clinical condition with an adequate washout prior to enrollment in the study.

Where this trial is running

Scottsdale, Arizona

• HonorHealth — Scottsdale, Arizona, United States (Recruiting)

Study contacts

• Study coordinator: Krystal Martinez

Conditions Advanced Solid Tumors; Metastatic Solid Tumors; ODC-IL2; Tumors